China VenturesChina Ventures 中华创投协会DEAL MARKETPLACE
Deals

18 Nov 2026China ventures news deskNewsdesk

Pfizer pays $330m upfront for China's Starna in $2.6bn CAR-T deal

Pfizer has licensed three preclinical in-vivo CAR-T programmes from China's Starna Therapeutics for $330m upfront and up to $2.3bn in milestones, plus royalties, in a deal announced on 18 November.

Pfizer pays $330m upfront for China's Starna in $2.6bn CAR-T deal
Image: China Ventures

What happened

Pfizer signed an exclusive licensing agreement with Starna Therapeutics, a China-based biotech working on RNA delivery for in-vivo CAR-T therapies. The deal, announced on 18 November, covers three early-stage programmes in autoimmune disease. Pfizer takes development, manufacturing and commercial rights outside Greater China, and will make initial clinical trial supply at its US facilities.

The numbers

ItemValue
Upfront$330m
MilestonesUp to $2.3bn
TotalAbout $2.6bn, plus royalties
ProgrammesThree, all preclinical

Why it matters

Out-licensing is now the main route for Chinese biotechs to capture international value without a US listing. The upfront is the number that matters to founders deciding between a China-only launch and a partner-led global one: $330m is real money before any trial reads out, and it validates RNA delivery for in-vivo CAR-T.

The counter-argument is that three preclinical programmes carry high attrition, and most of the $2.6bn is contingent. Pfizer's $10.5bn Innovent deal in May and its earlier 3SBio pact show a pattern rather than a one-off, which is the stronger signal for China biotech valuations.

What to watch

  • IND clearance and first-in-human dosing.
  • Milestone timing and any expansion of the Starna collaboration.
  • Whether other global pharma groups bid for similar Chinese assets.

Original source: BioSpace · 18 Nov 2026

All insights ↗